Breaking Barriers: Safely Targeting Obstructive Hypertrophic Cardiomyopathy at the Source : Episode 3
Opinion
Video
Aligning With 2023 ESC Guidelines in oHCM Treatment
Author(s):
Anjali Tiku Owens, MD, explores the role of cardiac myosin inhibitors in the treatment strategies for patients with obstructive hypertrophic cardiomyopathy (oHCM), in accordance with the latest European Society of Cardiology (ESC) Guidelines released in 2023.
EP: 1.Novel Cardiac Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause
EP: 2.Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment
Now Viewing
EP: 3.Aligning With 2023 ESC Guidelines in oHCM Treatment
EP: 4.Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes
EP: 5.Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice
- Where do cardiac myosin inhibitors fit into the treatment plans of your patients with oHMC, according to the most recent guidelines? ESC Guidelines 2023
- Initiating cardiac myosin inhibitors earlier?
- Use in patients who are severely symptomatic?
- MAPLE-HCM trial
Related Videos
Related Content
